Turoctocog Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Turoctocog alfa: From Hemophilia to Primary Release Disorder of Platelets
One-Sentence Summary
Turoctocog alfa is a recombinant human factor VIII (B-domain truncated) product, originally used to treat hemophilia. The TxGNN model predicts it may be effective for primary release disorder of platelets, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia (including the symptomatic form of hemophilia in female carriers) |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, turoctocog alfa is a recombinant factor VIII that replaces the missing FVIII activity in the intrinsic coagulation pathway. Its efficacy in hemophilia comes from correcting that specific deficiency.
Primary platelet release disorders arise from defects in platelet granule secretion or signalling, not from FVIII deficiency. There is therefore no clear mechanistic rationale for this prediction. The high TxGNN score most likely reflects shared "bleeding disorder" neighbours in the knowledge graph and is not clinical support.
Other predicted indications (all L5, all Hold, with no trials or literature):
| Rank | Predicted Disease | Score | Assessment |
|---|---|---|---|
| 2 | Pseudo-von Willebrand disease | 99.99% | Primary defect is platelet GPIbα gain-of-function; FVIII replacement alone would not address it. Only an indirect link, as FVIII is carried by VWF. |
| 3 | Glanzmann thrombasthenia | 99.99% | Caused by integrin αIIbβ3 deficiency; FVIII is not the missing component. No plausible link. |
| 4 | Scott syndrome | 99.95% | Defective phosphatidylserine exposure on platelets; extra FVIII does not restore the missing surface. Weak, indirect link. |
| 5 | Acquired coagulation factor deficiency | 99.95% | Most plausible candidate, since FVIII replacement could address acquired FVIII deficiency. Inhibitory autoantibodies (acquired hemophilia A) often make replacement ineffective. The category is also broad. |
| 6 | Bleeding diathesis due to a collagen receptor defect | 99.91% | Platelet-level defect independent of FVIII. |
| 7 | Hemorrhagic disorder due to a constitutional thrombocytopenia | 99.91% | Bleeding is driven by platelet count or function, not FVIII. |
| 8 | "Flood factor deficiency" | 99.61% | Not a standard disease name; the ontology entry should be verified. |
| 9 | Thrombotic thrombocytopenic purpura | 99.54% | Prothrombotic condition; a procoagulant could be harmful. This is a safety concern, not an opportunity. |
| 10 | Hereditary thrombocytosis with transverse limb defect | 99.52% | Thrombotic rather than bleeding risk; a procoagulant is not appropriate. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16111P | NOVOEIGHT Powder and Solvent for Solution for Injection 500IU/vial | Injection, powder, for solution | Not recorded in the data compiled for this report |
| SIN16110P | NOVOEIGHT Powder and Solvent for Solution for Injection 1000IU/vial | Injection, powder, for solution | Not recorded in the data compiled for this report |
| SIN16109P | NOVOEIGHT Powder and Solvent for Solution for Injection 250IU/vial | Injection, powder, for solution | Not recorded in the data compiled for this report |
| SIN16713P | NOVOEIGHT Powder and Solvent for Solution for Injection 2000IU/vial | Injection, powder, for solution | Not recorded in the data compiled for this report |
All four registrations are valid single-ingredient products, and none has been cancelled.
Safety Considerations
Please refer to the package insert for safety information.
Note that for thrombotic thrombocytopenic purpura (rank 9), the mechanistic review raises a concern: giving a procoagulant such as FVIII to a prothrombotic condition could be harmful.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no registered clinical trials and no literature, so it sits at evidence level L5. Primary platelet release disorders are platelet-function defects, not FVIII deficiencies, so there is no supporting mechanistic rationale. The same applies to most other predicted indications.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (currently missing, and a blocker for safety screening)
- Mechanism of action data, for example from DrugBank
- Approved indication text for the Singapore registrations
- A focused literature review on acquired coagulation factor deficiency (rank 5), the only candidate with a plausible mechanistic link, with attention to inhibitor-driven cases
- Verification of the "flood factor deficiency" ontology entry
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.